Skip to content

Accounts Payable at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$4.23B+5.8%
CTO
Citius Oncology, Inc.CTOR
$8.88M+15.7%
Inhibrx Biosciences, Inc. logo
Inhibrx Biosciences, Inc.INBX
$8.76M-1.5%
Corvus Pharmaceuticals logo
Corvus PharmaceuticalsCRVS
$4.7M+259%
Avalo Therapeutics logo
Avalo TherapeuticsAVTX
$356K-47.7%
Janux Therapeutics logo
Janux TherapeuticsJANX
$3.38M+43.6%

Other financials

Income statement

See full
Revenue-
Net income-$7.5M-13.1%
EPS (diluted)-$0.13+13.3%

Balance sheet

See full
Cash & equivalents$6.3M+1.3%
Total debt$456.9K+178%
Total equity$23.2M+135%
Total assets$29.7M+103%

Cash flow

See full
Operating cash flow-$4.4M+6.9%
CapEx$48.8K+14.5%
Free cash flow-$4.5M+6.7%

Valuation

See full
Market cap$155.39M+45.8%
Enterprise value$149.54M+52.3%

Returns & leverage

See full
Return on equity-187.2%
Debt / equity0.0×
Current ratio1.2×-1.8×

Where this comes from

Reported directly by TuHURA Biosciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent.

The official record: TuHURA Biosciences, Inc.’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →

Ask your AI about TuHURA Biosciences, Inc.'s accounts payable.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is TuHURA Biosciences, Inc.'s accounts payable?
TuHURA Biosciences, Inc. (HURA) reported accounts payable of $5.86M in Q1 2026.
How has TuHURA Biosciences, Inc.'s accounts payable changed year-over-year?
TuHURA Biosciences, Inc.'s accounts payable increased by 26.9% year-over-year, from $4.62M to $5.86M.
What is the long-term trend for TuHURA Biosciences, Inc.'s accounts payable?
Over 3 years (2022 to 2025), TuHURA Biosciences, Inc.'s accounts payable has grown at a 27.1% compound annual growth rate (CAGR), from $2.69M to $5.52M.
What does accounts payable mean?
Amounts owed to suppliers and vendors for goods and services received but not yet paid. A primary source of short-term trade financing.